Existing studies have reported that NR6A1 is aberrantly expressed in a variety of solid tumors, e.g., hepatocellular carcinoma (Lin et al., 2022), gastric carcinoma (Zhou et al., 2020), and that aberrant expression is closely associated with tumor progression. The gene discussed is NR6A1; the disease is neoplasm.